- Conditions
- Diabetes Mellitus, Obesity
- Interventions
- Trodusquemine (MSI-1436)
- Drug
- Lead sponsor
- Genaera Corporation
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 103
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Type 2 Diabetes Mellitus, Obesity
- Interventions
- Allergan Adjustable Gastric Band Surgery, Intensive Medical Diabetes & Weight Management (Why WAIT) - Band Group, Roux-en-Y Gastric Bypass (RYGB) Surgery, Intensive Medical Diabetes & Weight Management (Why WAIT) - Bypass Group
- Device · Other · Procedure
- Lead sponsor
- Joslin Diabetes Center
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Interventions
- Orforglipron, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 35
- States / cities
- Sun City West, Arizona • Tucson, Arizona • San Ramon, California + 31 more
- Conditions
- Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)
- Interventions
- Placebo, Enicepatide
- Drug
- Lead sponsor
- Carmot Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Guntersville, Alabama • Yuma, Arizona + 45 more
- Conditions
- Healthy, Overweight, Obesity, Type 2 Diabetes
- Interventions
- LY4086940, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 216 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- Daytona Beach, Florida • Miami, Florida • Dallas, Texas + 1 more
- Conditions
- Obesity, Overweight
- Interventions
- Retatrutide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 19
- States / cities
- Riverside, California • Atlantis, Florida • Orlando, Florida + 16 more
- Conditions
- Overweight or Obesity, CKD, Type 2 Diabetes
- Interventions
- Retatrutide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 19
- States / cities
- Chandler, Arizona • Mesa, Arizona • Scottsdale, Arizona + 15 more
- Conditions
- Obesity, Overweight
- Interventions
- Bimagrumab, Tirzepatide, Bimagrumab Placebo, Tirzepatide Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 25
- States / cities
- Yuma, Arizona • Lake Forest, California • Long Beach, California + 22 more
- Conditions
- Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes
- Interventions
- ALV-100, Placebo
- Drug
- Lead sponsor
- Alveus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Miami, Florida • Columbus, Ohio
- Conditions
- Obesity, Overweight, Type 2 Diabetes Mellitus
- Interventions
- Maridebart Cafraglutide, Placebo
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 592 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 29
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 20 more
- Conditions
- Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus
- Interventions
- aleniglipron, Placebo
- Drug
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 1,100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 67 more
- Conditions
- Overweight or Obesity, Diabetes Mellitus, Type 2, Physical Inactivity
- Interventions
- Physical Activity, Delayed intervention
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 880 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Weight Loss
- Interventions
- VK2735
- Drug
- Lead sponsor
- Viking Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 135
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 119 more
- Conditions
- Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
- Interventions
- ALN-4324, Placebo
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 7
- States / cities
- Montclair, California • Washington D.C., District of Columbia • Miami, Florida + 3 more
- Conditions
- Chronic Kidney Disease
- Interventions
- NNC0519-0130, Placebo, Semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 465 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 18
- States / cities
- San Dimas, California • San Ramon, California • Aurora, Colorado + 14 more
- Conditions
- Obesity, Overweight
- Interventions
- Tirzepatide, Placebo
- Drug · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 579 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 45
- States / cities
- Huntington Park, California • Los Angeles, California • Montclair, California + 42 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Gastric bypass for diabetic patients <35 BMI
- Procedure
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea
- Interventions
- Retatrutide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,335 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 33 more
- Conditions
- Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D
- Interventions
- Tirzepatide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 10
- States / cities
- Northridge, California • Aurora, Colorado • Denver, Colorado + 7 more
- Conditions
- Obesity, Overweight, Diabetes Mellitus, Type 2
- Interventions
- NNC0487-0111, Semaglutide, Placebo (matched to NNC0487-0111), Placebo (matched to semaglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 10
- States / cities
- Hollywood, Florida • Orange City, Florida • Weston, Florida + 7 more
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Interventions
- Orforglipron, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 35
- States / cities
- Sun City West, Arizona • Tucson, Arizona • San Ramon, California + 31 more
- Conditions
- Obesity, Diabetes Mellitus, Type 2
- Interventions
- Survodutide, Placebo
- Combination Product
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 755 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 34
- States / cities
- Anniston, Alabama • Phoenix, Arizona • Spring Valley, California + 31 more
- Conditions
- Diabetes Mellitus and Heart Failure
- Interventions
- LIK066, Placebo, Empagliflozin
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 21
- States / cities
- Huntsville, Alabama • Carmichael, California • Concord, California + 18 more
- Conditions
- Type 2 Diabetes, Overweight, ASCVD
- Interventions
- Dulaglutide, Semaglutide, Tirzepatide, Sitagliptin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60,000 participants
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts